U.S. markets open in 28 minutes

Constellation Pharmaceuticals, Inc. (CNST)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.00+0.18 (+0.79%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close22.82
Open22.94
Bid22.99 x 1000
Ask32.18 x 900
Day's Range21.98 - 23.20
52 Week Range11.66 - 59.49
Volume321,553
Avg. Volume520,587
Market Cap1.092B
Beta (5Y Monthly)2.90
PE Ratio (TTM)N/A
EPS (TTM)-2.77
Earnings DateOct 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

    CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7374769. About Constellation PharmaceuticalsConstellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.ContactsKia Khaleghpour, PhD Vice President, Investor Relations and Communications Constellation Pharmaceuticals +1 617-844-6859 kia.khaleghpour@constellationpharma.comRonald Aldridge Senior Director, Investor Relations Constellation Pharmaceuticals +1 617-714-0539 ron.aldridge@constellationpharma.comLauren Arnold Media Relations MacDougall Biomedical Communications +1 781-235-3060 larnold@macbiocom.com

  • Hedge Funds Are Betting On Constellation Pharmaceuticals, Inc. (CNST)
    Insider Monkey

    Hedge Funds Are Betting On Constellation Pharmaceuticals, Inc. (CNST)

    We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

  • GlobeNewswire

    Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

    CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences.  Jigar Raythatha, CEO, will present at: * The H.C. Wainwright Global Investment Conference at 1:00 PM EDT on September 14 * The Cantor Global Healthcare Conference at 1:20 PM EDT on September 17 Live audio webcasts of Mr. Raythatha’s presentations and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events.  The audio webcast replays will be available for 30 days following the live presentation.About Constellation PharmaceuticalsConstellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.ContactKia Khaleghpour, Ph.D. Vice President, Investor Relations and Communications Constellation Pharmaceuticals +1 617-844-6859 kia.khaleghpour@constellationpharma.comRonald Aldridge Investor Relations Constellation Pharmaceuticals +1 617-714-0539 ron.aldridge@constellationpharma.comLauren Arnold Media Relations MacDougall Biomedical Communications +1 781-235-3060 larnold@macbiocom.com